TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio (NASDAQ: TELA) has announced the approval of inducement grants by its Board's Compensation Committee. The grants consist of restricted stock units covering 7,200 shares of common stock, awarded to thirteen newly-hired employees on February 19, 2025. These grants, made under Nasdaq Rule 5635(c)(4), serve as employment compensation and incentives for new hires. The restricted stock units will vest equally over four years, contingent on continued employment with TELA Bio through the specified vesting dates.
TELA Bio (NASDAQ: TELA) ha annunciato l'approvazione delle concessioni di indennità da parte del Comitato per la Compensazione del suo Consiglio. Le concessioni consistono in unità di azioni vincolate che coprono 7.200 azioni di azioni ordinarie, assegnate a tredici nuovi dipendenti il 19 febbraio 2025. Queste concessioni, effettuate ai sensi della Regola 5635(c)(4) del Nasdaq, fungono da compenso per l'occupazione e incentivi per i nuovi assunti. Le unità di azioni vincolate matureranno in modo uniforme su quattro anni, a condizione che l'impiego con TELA Bio continui fino alle date di maturazione specificate.
TELA Bio (NASDAQ: TELA) ha anunciado la aprobación de las concesiones de incentivo por parte del Comité de Compensación de su Junta. Las concesiones consisten en unidades de acciones restringidas que cubren 7,200 acciones de acciones comunes, otorgadas a trece empleados recién contratados el 19 de febrero de 2025. Estas concesiones, realizadas bajo la Regla 5635(c)(4) de Nasdaq, sirven como compensación laboral e incentivos para los nuevos empleados. Las unidades de acciones restringidas se adquirirán de manera uniforme durante cuatro años, dependiendo de la continuidad del empleo con TELA Bio hasta las fechas de adquisición especificadas.
TELA Bio (NASDAQ: TELA)는 이사회 보상 위원회에서 유인 보조금 승인을 발표했습니다. 이 보조금은 7,200주의 보통주를 포함하는 제한 주식 단위로, 2025년 2월 19일에 새로 채용된 13명의 직원에게 수여됩니다. 이 보조금은 나스닥 규칙 5635(c)(4)에 따라 이루어지며, 신규 채용에 대한 고용 보상 및 인센티브 역할을 합니다. 제한 주식 단위는 4년 동안 균등하게 분할되어, 지정된 분할 날짜까지 TELA Bio와 계속 고용 관계를 유지할 경우에 해당합니다.
TELA Bio (NASDAQ: TELA) a annoncé l'approbation des attributions d'incitation par le Comité de Rémunération de son Conseil. Les attributions consistent en des unités d'actions restreintes couvrant 7 200 actions ordinaires, accordées à treize nouveaux employés le 19 février 2025. Ces attributions, effectuées conformément à la règle 5635(c)(4) de Nasdaq, servent de compensation à l'emploi et d'incitations pour les nouvelles recrues. Les unités d'actions restreintes vont se libérer progressivement sur quatre ans, sous réserve de la poursuite de l'emploi chez TELA Bio jusqu'aux dates de libération spécifiées.
TELA Bio (NASDAQ: TELA) hat die Genehmigung von Anreizvergaben durch den Vergütungsausschuss seines Vorstands bekannt gegeben. Die Vergaben bestehen aus eingeschränkten Aktieneinheiten, die 7.200 Aktien von Stammaktien abdecken, die am 19. Februar 2025 an dreizehn neu eingestellte Mitarbeiter vergeben werden. Diese Vergaben, die gemäß der Nasdaq-Regel 5635(c)(4) erfolgen, dienen als Beschäftigungsvergütung und Anreize für neue Mitarbeiter. Die eingeschränkten Aktieneinheiten werden gleichmäßig über vier Jahre verteilt, vorausgesetzt, dass das Beschäftigungsverhältnis mit TELA Bio bis zu den festgelegten Vesting-Daten fortgesetzt wird.
- Addition of 13 new employees indicates company growth
- Implementation of employee retention strategy through equity compensation
- Potential shareholder dilution from 7,200 new shares
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 7,200 shares of its common stock to thirteen newly-hired employees, with a grant date of February 19, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
FAQ
How many shares were granted in TELA Bio's February 2025 inducement grants?
What is the vesting schedule for TELA Bio's February 2025 inducement grants?
How many new employees received TELA Bio's February 2025 inducement grants?
Under which Nasdaq rule were TELA Bio's February 2025 inducement grants issued?
